ONC
BeOne Medicines Ltd.
ONC has the edge over UNH overall, supported by stronger fundamentals.
UNH
UnitedHealth Group Incorporated
UNH has lower modeled downside risk, despite its lower overall score.
ONC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
ONC's revenue, profitability, cash flow and balance sheet are all currently healthy.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ONC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 52x | $416 | — |
| Cheap | 62x | $37.70 | -91% |
| Fair | 72x | $43.95 | -89% |
| Expensive | 650x | $396 | -4.8% |
Historical ranges are pointers, not guarantees.
ONC's PE is 52x, but its earnings don't support one, so it isn't a reliable read right now.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH has the edge over ONC in the historical PE scenario, which offers more potential upside but is not a forecast.
ONC Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
ONC has the edge over UNH on the outlook, with more favorable revenue expectations.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ONC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.61 | +1425% |
| Q2 2026 | $0.44 | +$0.57 |
| Q1 2026 | $0.34 | +$0.62 |
| Q4 2025 | $0.19 | +$0.66 |
| Q3 2025 | $0.04 | +$0.67 |
| Q2 2025 | -$0.13 | +$0.26 |
| Q1 2025 | -$0.28 | +$0.30 |
| Q4 2024 | -$0.47 | +$0.18 |
ONC has the edge over UNH on earnings, with more consistent year-over-year improvement.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH's earnings per share have fallen from their peak: $17.55 over the past year, against $23.89 in early 2025.
ONC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | +34% |
| Q2 2026 | $1.7B | +30% |
| Q1 2026 | $1.5B | +35% |
| Q4 2025 | $1.5B | +33% |
| Q3 2025 | $1.4B | +41% |
| Q2 2025 | $1.3B | +42% |
| Q1 2025 | $1.1B | +49% |
| Q4 2024 | $1.1B | +78% |
ONC has the edge over UNH on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 22% | +11 points |
| Q2 2026 | 19% | +12 points |
| Q1 2026 | 17% | +16 points |
| Q4 2025 | 12% | +19 points |
| Q3 2025 | 12% | +24 points |
| Q2 2025 | 6.7% | +18 points |
| Q1 2025 | 1% | +36 points |
| Q4 2024 | -7% | +54 points |
ONC has the edge over UNH on profitability, with a higher operating margin.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH's operating margin was 5.8% last quarter, up 2 points from the same quarter a year ago.
ONC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $473.5M | +34% |
| Q2 2026 | $435.3M | +98% |
| Q1 2026 | $160.5M | +$172.9M |
| Q4 2025 | $379.8M | +$397.1M |
| Q3 2025 | $354.5M | +548% |
| Q2 2025 | $219.8M | +$425.3M |
| Q1 2025 | -$12.3M | +$452.8M |
| Q4 2024 | -$17.3M | +$361.3M |
ONC has the edge over UNH on cash flow, with more consistent year-over-year improvement.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
ONC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -3.4x | Net Cash |
| Q2 2026 | -3.7x | Net Cash |
| Q1 2026 | -4.4x | Net Cash |
| Q4 2025 | -6.0x | Net Cash |
| Q3 2025 | -9.5x | Net Cash |
| Q2 2025 | -20.2x | Net Cash |
ONC has the edge over UNH on leverage, with a lower net debt burden relative to earnings.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ONC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.6 | Overbought |
| Stochastic | 87.7 | Overbought |
ONC's weekly RSI is 71 (overbought) and its Stochastic is 88 (overbought).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ONC PE vs Healthcare Sector
| Metric | ONC | Sector median | Relative |
|---|---|---|---|
| PE | 52x | 26x | 103% above |
| PE % | 2 | 29 | 27 pts below |
ONC is trading at 52x earnings, a 103% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH has the edge over ONC on valuation relative to its sector.
ONC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $376.7 | 10% above |
| 20 week MA | $352.8 | 18% above |
| 50 week MA | $326.9 | 27% above |
| 100 week MA | $298.0 | 40% above |
| 200 week MA | $244.9 | 70% above |
ONC has the edge over UNH on trend strength, trading above more of its moving averages.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
ONC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $167.2 | $263.7 | +58% |
| 2021 | $263.7 | $268.6 | +1.9% |
| 2022 | $268.6 | $226.1 | -16% |
| 2023 | $226.1 | $180.4 | -20% |
| 2024 | $180.4 | $181.9 | +0.8% |
| 2025 | $181.9 | $312.4 | +72% |
| 2026 YTD | $312.4 | $416.0 | +33% |
ONC has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.